Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Elucidating the Molecular Mechanism of Action of the First-in-Human SMARCA2 Selective Degrader PRT3789

Friday, April 25, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the introduction of PRT3789, the first-in-human SMARCA2 selective degrader. This innovative compound aims to enhance targeted therapies by elucidating its molecular mechanism of action. The study highlights the potential benefits of PRT3789 in clinical applications, marking a significant step forward in biopharmaceutical research.
Price reaction · baseline $0.8754 (2025-04-25T16:01:00.000Z) · hit during market hours · 1 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a novel SMARCA2 selective degrader, PRT3789.
  • Potential for significant advancements in targeted therapies.
  • First-in-human study indicating promising therapeutic applications.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Min Wang, Miles Cowart, Joy Cote, Justin Kurian, Stephanie Rodgers, Chaoyi Xu, Corey Basch, Philip Pitis, Klare Bersch, Raul Leal, Liang Lu, Michael Hulse, Jack Carter, Andrew Moore, Alexander Grego, Joseph Rager, Tom Emm, Koichi Ito, Neha Bhagwat, Andrew Combs, Sandy Geeganage, Peggy Scherle.

Frequently Asked Questions

What is PRT3789?

PRT3789 is the first-in-human SMARCA2 selective degrader aimed at enhancing targeted therapies.

What is the significance of SMARCA2?

SMARCA2 is a target for developing therapies that may improve treatment outcomes in certain cancers.

What does 'selective degrader' mean?

A selective degrader specifically targets and degrades certain proteins, potentially improving therapeutic efficacy.

Who are the researchers involved in the study?

The study involves multiple researchers including Min Wang, Miles Cowart, and Joy Cote.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 selective degrader biopharmaceuticals clinical research
Last updated: Apr 25, 2025

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →